Oppenheimer Maintains Outperform on Abeona Therapeutics, Lowers Price Target to $21
Oppenheimer analyst Jeff Jones maintains Abeona Therapeutics (NASDAQ:ABEO) with a Outperform and lowers the price target from $22 to $21.
Stocks · News reference
Abeona Therapeutics shares are trading lower after the company reported worse-than-expected Q2 financial results.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Abeona Therapeutics Q2 2026 Earnings Call Transcript
Abeona Therapeutics (NASDAQ:ABEO) held its second-quarter earnings conference call on Thursday. Below is the complete transcript from the call. This content is powered by Benzinga APIs. For comprehensive financial data
Abeona Therapeutics Q2 EPS $(0.35) Misses $(0.23) Estimate, Sales $11.380M Miss $12.239M Estimate
Abeona Therapeutics (NASDAQ:ABEO) reported quarterly losses of $(0.35) per share which missed the analyst consensus estimate of $(0.23) by 52.17 percent. This is a 5.41 percent increase over losses of $(0.37) per share